

# BUREAU OF CUSTOMS

MAKABAGONG ADUANA, MATATAG NA EKONOMIYA

AOCG Memo No. 88 - 2023

BOC-09-37983

#### **MEMORANDUM**

TO

ALL DISTRICT COLLECTORS ALL SUB-PORT COLLECTORS ALL OTHERS CONCERNED

**FROM** 

ATTY. EDWARD JAMES A. DY BUCQ

Deputy Commissioner

Assessment and Operations Coordinating Group

**SUBJECT** 

Food and Drug Administration (FDA) Recommendation for

The Release of Donated Pharmaceutical Products from

World Health Organization (WHO) to Department of Health

(DOH)

DATE

10 February 2023

Forwarding the herein attached letter dated 24 January 2023 from Director Jesusa Joyce N. Cirunay, Center for Food Regulation and Research, FDA, addressed to Anthony B. Cu, MD, MPM-HSD, MPH-EOH, CESE, Director IV, Department of Health-Disease Prevention and Control Bureau, recommending clearance for the release of foreign drug donations from WHO to the DOH with the information that the release shall be subject to the following conditions:

- 1. the release of the said pharmaceutical products is intended for patients with Leprosy,
- 2. shall have a shelf-life of not less than 12 months at the time of arrival;
- 3. the labels (primary, secondary, and product information) shall be in the English language; and
- 4. the clearance is without prejudice to tariff rules and customs regulations.

For information and appropriate action.





## AOCG Memo No. 88-7023 p. 2

Republic of the Philippines Department of Health

### FOOD AND DRUG ADMINISTRATION



#### CLEARANCE LETTER

24 January 2023



## ANTHONY B. CU, MD, MPM-HSD, MPH-EOH, CESE

Director IV

Department of Health-Disease Prevention and Control Bureau San Lazaro Compound, Rizal Avenue, Sta. Cruz, Manila, 1003

Subject: Clearance of Foreign Drug Donations

Dear Dr. Cu:



Please be informed that this Office recommends clearance for the release of the following products as donation by the World Health Organization (WHO) Philippine Country Office - Bldg. 3, DOH, San Lazaro Compound, Rizal Avenue, Sta. Cruz, Manila 1003 to the Department of Health (DOH) - Disease Prevention and Control Bureau located at the abovementioned address:

Product Description (Generic/Dosage Strength and Form/Brand)	Batch/Lot No.	Expiry Dat	e Quantity
Multidrug Therapy (MDT)			
Multibacillary (MB) Adult			
[MDT-Combi]			
Each Blister Pack			
contains:			
Rifampicin (Rimactane) 300			
mg Capsule x 2 + Clofazimine			
(Lamprene) 100 mg Capsule x			
3 + Clofazimine (Lamprene)			
50 mg Capsule x 27 +			
Dapsone 100 mg Tablet x 28			14.076 PI
Packaging: Per Large Box: 8	MB7575	31 January 20	14,976 Blister
Boxes of 6 Alu-PVC Blister			Packs
Packs (48 Blister Packs)			
Manufacturer/ Address:			
Sandoz Private Limited – Plot			
No. 8 A/2 and 8-B, TTC		REPUBLIC	OF THE PHILIPPINES
Industrial Area, Kalwe Block,		BURE	AU OF CUSTOMS
Village Dighe, Navi Mumbai,	1.1	OFFICE OF TH	E DEPUTY COMMISSIONER IONS COORDINATING GROUP (AOCG)
400708, India	A	marries (minoria d	CANADA PROPERTY AND AND PERSONAL DESIGNATION.
Storage conditions: Store at		143	GEWED
temperatures not exceeding	1 of 10		
25°C. BUREAL PORT OPE	PATIONS SER	BY: C. NO	
REC	FIVE	DADE & TIME:	2-7-23 1:50
l ccc	3 0 8 2023		
T E.L	0 0 2023		
BY: Norrel E	ngalla TIME:	1/10	OR FE

Civic Drive, Filinvest City, Alabang 1781 Muntinlupa, Philippines Trunk Line +63 2 857 1900 Fax +63 2 807 0751 Website: www.fda.gov.ph Email: info@fda.gov.ph







Multidrug Therapy (MDT) Multibacillary (MB) Child [MDT - Combi] Each Blister Pack contains: Rifampicin (Rimactane) 300 mg Capsule x 1 + Rifampicin (Rimactane) 150 mg Capsule x 1 + Clofazimine (Lamprene) 50 mg Capsule x 16 + Dapsone 100 mg Tablet x 28 Packaging: Per Large Box: 8 Boxes of 6 Alu-PVC Blister Packs (48 Blister Packs) Manufacturer/ Address: Sandoz Private Limited – Plot No. 8 A/2 and 8-B, TTC Industrial Area, Kalwe Block, Village Dighe, Navi Mumbai, 400708, India Storage conditions: Store at temperatures not exceeding 25°C.	MF9008	31 October 2025	1,152 Blister Packs
--	--------	-----------------	------------------------

The release of said donated pharmaceutical products, intended for patients with Leprosy, is on the condition that the said products shall have:

- a shelf-life of not less than 12 months at the time of arrival; and 1.
- 2. labels (primary, secondary, and product information) in English language.

This clearance is without prejudice to tariff rules and customs regulations.

Very truly yours,

By Authority of the Director General: Per FDA Order Yo. 2016-005

JESUSA JOYCE N. CIRUNAY, RPh

Director IV, Center for Drug Regulation and Research

Amt. Paid: PHP 1,020,00

OR#: Sequence Number: 11723543330

Date: 17 January 2023

cc: Maria Soledad Q. Antonio, MD, PhD, MPH, DPAFP, CESE

Director IV, Bureau of International Health Cooperation

Yogi Filemon L. Ruiz

Commissioner, Bureau of Customs